Advertisement
ACRV vs ALLR
Which Stock Would AI Choose? Acrivon Therapeutics (ACRV) vs. Allarity Therapeutics (ALLR) Stock Comparison
Key Takeaways
- ACRV is a clinical-stage precision oncology company backed by a roughly $90 million cash position, while ALLR operates with a smaller cash balance of about $27 million, creating materially different risk profiles.
- Both companies are pre-revenue biotechnology developers, meaning their stock performance is driven primarily by clinical catalysts, regulatory milestones, and financing events rather than earnings.
- ACRV is advancing a multi-asset oncology pipeline, whereas ALLR is concentrated around a single lead asset, stenoparib, with an accompanying companion diagnostic.
- Relative performance and market positioning diverge sharply: ACRV holds a "Strong Buy" analyst consensus, while ALLR has a history of higher volatility and financing-driven dilution.
- Explore ACRV Major News and ACRV Today's Price Move, along with ALLR Major News and ALLR Today's Price Move, for the latest developments on each ticker.
- For automated, data-driven analysis of these and thousands of other tickers, explore Trending AI Robots.
Introduction
Acrivon Therapeutics (ACRV) and Allarity Therapeutics (ALLR) are both clinical-stage biopharmaceutical companies pursuing precision oncology, yet they sit at opposite ends of the small-cap risk spectrum. Investors weighing this stock comparison are typically evaluating two very different approaches: one centered on a broad, platform-driven pipeline and the other on a single late-stage asset paired with a biomarker test. Understanding how these firms differ in business model, clinical momentum, balance-sheet strength, and market sentiment is essential for anyone assessing their relative performance and market positioning in the current environment.
ACRV Overview and Recent Performance
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines using its proprietary AP3 platform (Generative Phosphoproteomics), which aims to predict patient response to specific drug candidates. Its lead program, ACR-368 (prexasertib), is in a registrational-intent Phase 2b study in endometrial cancer, while ACR-2316, a dual WEE1/PKMYT1 inhibitor, is advancing through dose expansion in Phase 1/2. A CDK11 inhibitor program remains in preclinical development.
In recent weeks, ACRV has drawn analyst attention, maintaining a "Strong Buy" consensus with price targets from firms such as Jefferies, Oppenheimer, and H.C. Wainwright. The company reported a second-quarter net loss of roughly $18 million, with cash, cash equivalents, and investments of about $90 million as of June 30, 2026, a runway management projects into the fourth quarter of 2027. Sentiment has been shaped by anticipated clinical data readouts in the second half of 2026 and the breadth of its pipeline relative to peers.
ALLR Overview and Recent Performance
Allarity Therapeutics is a Phase 2 clinical-stage pharmaceutical company developing stenoparib, an orally available dual inhibitor of PARP1/2 and tankyrase 1/2, in advanced ovarian cancer and relapsed small cell lung cancer. Its strategy pairs the drug with a proprietary DRP (Drug Response Predictor) companion diagnostic designed to identify patients most likely to benefit.
Recent market activity for ALLR has been influenced by a series of operational milestones, including completion of Phase 3-ready manufacturing of stenoparib, new patent allowances for its companion diagnostic, and the filing of a registration statement for a related special purpose acquisition company (SPAC). The company reported a second-quarter net loss of about $3.4 million and held roughly $26.9 million in cash and restricted cash as of June 30, 2026. Shares have traded within a wide range over the past year, reflecting elevated volatility and sensitivity to financing and clinical news.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a broader universe of hundreds of automated strategies that collectively trade thousands of different tickers. Because each bot has its own trading style, timeframe, strategy, performance history, and set of underlying tickers, only those best suited to current market conditions earn a place in this featured section. Investors can browse bots across multiple performance tiers and statistical profiles, making it easier to identify approaches that align with their risk tolerance and objectives. To see which AI strategies are currently leading the market, explore Trending AI Robots.
Head-to-Head Comparison
The clearest contrast between these two names lies in diversification versus concentration. ACRV operates a multi-asset pipeline spanning several mechanisms of action, which distributes clinical risk but also demands higher research and development spending. ALLR is effectively a single-asset story, offering sharper upside tied to stenoparib's success but leaving less room to absorb a clinical setback.
On the balance sheet, ACRV holds a meaningfully larger cash buffer, while ALLR has relied on promissory notes, equity lines of credit, and a SPAC structure to fund operations, a dynamic that has historically pressured shareholders through dilution. Growth drivers also differ: ACRV is anchored by near-term Phase 2b data and a planned Phase 3 trial, whereas ALLR is working toward a potential pivotal ovarian cancer trial while expanding into lung cancer through a VA-funded study. Market sentiment reflects these contrasts, with ACRV enjoying broader analyst coverage and ALLR exhibiting wider trading ranges and greater financing-related volatility.
Tickeron AI Verdict
Based on observable factors such as trend consistency, balance-sheet stability, pipeline breadth, and the presence of near-term clinical catalysts, Tickeron's AI would likely favor ACRV in the current environment. The combination of a stronger cash runway, a diversified asset portfolio, and consistent "Strong Buy" analyst sentiment suggests more stable relative positioning. That said, ALLR retains meaningful event-driven potential tied to its ovarian cancer program and companion-diagnostic strategy. The AI's assessment is probabilistic rather than definitive, and either name could shift positioning quickly on new clinical or financing data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRV is a Hold and ALLR is a Hold.
Momentum Indicator for ACRV turns negative, indicating new downward trend
ACRV saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 73 similar instances where the indicator turned negative. In 67 of the 73 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ACRV turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 30 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
ACRV moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACRV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACRV entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRV's RSI Indicator exited the oversold zone, 24 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRV advanced for three days, in 180 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
ACRV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.796) is normal, around the industry mean (3.498). P/E Ratio (-0.856) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ACRV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ALLR's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for ALLR moved out of overbought territory on November 04, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 instances where the indicator moved out of the overbought zone. In 14 of the 14 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALLR as a result. In 64 of 67 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
ALLR moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ALLR moved below the 200-day moving average on October 12, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALLR broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALLR entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for ALLR just turned positive on October 21, 2026. Looking at past instances where ALLR's MACD turned positive, the stock continued to rise in 25 of 31 cases over the following month. The odds of a continued upward trend are 81%.
Following a +29.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLR advanced for three days, in 144 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.361) is normal, around the industry mean (3.498). P/E Ratio (-1.227) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. ALLR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| ACRV | ALLR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 86% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| Advances ODDS (%) | 8 days ago 89% | 9 days ago 82% |
| Declines ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACRV’s FA Score shows that 0 FA rating(s) are green while ALLR’s FA Score has 0 green FA rating(s).
- ACRV’s FA Score: 0 green, 5 red.
- ALLR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACRV’s TA Score shows that 4 TA indicator(s) are bullish while ALLR’s TA Score has 3 bullish TA indicator(s).
- ACRV’s TA Score: 4 bullish, 6 bearish.
- ALLR’s TA Score: 3 bullish, 7 bearish.
Price Growth
ACRV (@Biotechnology) experienced а -5.99% price change this week, while ALLR (@Biotechnology) price change was -19.45% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
ACRV is expected to report earnings on Nov 12, 2026.
ALLR is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ACRV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACRV has been loosely correlated with IMRX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRV jumps, then IMRX could also see price increases.
| Ticker / NAME | Correlation To ACRV | 1D Price Change % | ||
|---|---|---|---|---|
| ACRV | 100% | -0.63% | ||
| IMRX - ACRV | 51% Loosely correlated | +5.48% | ||
| ALLR - ACRV | 48% Loosely correlated | -3.49% | ||
| CRMD - ACRV | 43% Loosely correlated | -1.83% | ||
| DNA - ACRV | 41% Loosely correlated | -2.91% | ||
| SANA - ACRV | 38% Loosely correlated | -1.42% | ||
More | ||||
ALLR and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALLR has been closely correlated with TAOX. These tickers have moved in lockstep 87% of the time. This A.I.-generated data suggests there is a high statistical probability that if ALLR jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To ALLR | 1D Price Change % | ||
|---|---|---|---|---|
| ALLR | 100% | -3.49% | ||
| TAOX - ALLR | 87% Closely correlated | -5.15% | ||
| NRXP - ALLR | 81% Closely correlated | -0.84% | ||
| ACRV - ALLR | 48% Loosely correlated | -0.63% | ||
| BCTX - ALLR | 35% Loosely correlated | -1.07% | ||
| IVVD - ALLR | 34% Loosely correlated | -3.66% | ||
More | ||||